SEC filings and other documents

Regulatory approval awaits only a vendor inspection, with launch readiness and funding secured.

OLC offers a high-potency, low-pill solution for hyperphosphatemia with near-term FDA approval expected.

OLC approval hinges on FDA facility inspection; net loss narrows and cash runway extends into 2027.

OLC offers a high-potency, low pill burden solution for hyperphosphatemia, nearing FDA approval.

OLC targets hyperphosphatemia's unmet needs with low pill burden and strong launch readiness.

PDUFA decision for a novel phosphate binder may transform dialysis care with a streamlined launch.

Regulatory delay for OLC is manufacturing-related, with rapid launch and funding readiness upon approval.